东宝生物(300239.SZ)发布上半年业绩，归母净利润3696.73万元，下降28.00%

Core Viewpoint - Dongbao Bio (300239.SZ) reported a decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for the first half of 2025 was 369 million yuan, a year-on-year decrease of 16.93% [1] - The net profit attributable to shareholders of the listed company was 36.97 million yuan, reflecting a year-on-year decrease of 28.00% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 33.44 million yuan, down 27.41% year-on-year [1] - Basic earnings per share were reported at 0.0629 yuan [1]